Masimo v. Apple (22-1634): Federal Circuit splits on blood-monitoring patent validity
Masimo Corp. challenged Apple Inc. over US10631765B1, covering multi-stream noninvasive blood constituent measurement — a technology central to wearable health sensing. The Federal Circuit issued a mixed ruling, affirming-in-part and reversing-in-part, across 517 days of appellate proceedings. The recorded basis of termination is Appeal Dismissed in Part.
Masimo v. Apple: a split Federal Circuit ruling on wearable health IP
Masimo Corporation filed this appeal at the Court of Appeals for the Federal Circuit on 13 April 2022, naming Apple Inc. as respondent. The dispute centres on US10631765B1, directed to a multi-stream data collection system for noninvasive measurement of blood constituents — a technology class directly implicated in Apple Watch health-sensing features. The case falls squarely within the patentability/invalidity/cancellation category.
The case closed on 12 September 2023 after 517 days. The recorded basis of termination is 'Appeal Dismissed in Part.' The docket verdict separately states that the court ordered: 'AFFIRMED-IN-PART AND REVERSED-IN-PART.' These two characterisations are reported as-is from the record; the reader should note that they present different framings of the disposition, and the specific scope of each part is not further detailed in the available public record.
The 517-day duration is consistent with a substantive Federal Circuit merits appeal involving patentability questions. The mixed affirm/reverse disposition suggests the court found merit in at least some of Masimo's appellate arguments while sustaining other aspects of the decision below — though which claims or grounds fall into which category is not specified in the available record. The precise commercial and enforcement implications therefore remain contingent on the full written opinion.
See Complete Case & Patent Analysis →Filing to Appeal Dismissed in Part in 517 days
517 days from filing to close — typical Federal Circuit appeal runs 12–18 months
US10631765B1 — multi-stream noninvasive blood constituent measurement
Any organisation developing wearable devices that collect physiological data through noninvasive optical or spectroscopic sensing — including blood oxygen, pulse, or related constituent monitoring — should treat US10631765B1 as a live FTO concern. The Federal Circuit's partial reversal means that at least some claim scope under this patent may have been restored or remains unresolved. A clearance analysis premised on earlier invalidity findings may no longer be reliable.
Official order — verbatim text
The Federal Circuit's order — 'AFFIRMED-IN-PART AND REVERSED-IN-PART' on patentability grounds — reflects a standard appellate review for legal error in an invalidity/cancellation proceeding. A reversal at this level requires the panel to have identified a specific legal error in the tribunal below; affirmance reflects no such error found in the remaining portions. The recorded basis of termination, 'Appeal Dismissed in Part,' indicates a further procedural element; the precise scope of each component is not detailed in the available public record.
Federal Circuit splits: what the mixed ruling means for both parties
Affirmed-in-part, reversed-in-part: what the Federal Circuit decided
A mixed Federal Circuit disposition means the appellate panel found no reversible error in some aspects of the lower tribunal's patentability determination, while identifying reversible error in others. Neither party achieved a complete win. The recorded basis of termination — 'Appeal Dismissed in Part' — indicates a further procedural dimension: part of the appeal did not reach a merits disposition at all.
Split appellate dispositionMasimo: partial reversal preserves some appellate gains
To the extent the Federal Circuit reversed the decision below, Masimo secured a meaningful appellate outcome — claims or grounds previously decided against it may be restored or remanded for further proceedings. However, the affirmed portions represent claims or grounds where the lower decision stands against Masimo. The specific claims affected are not identified in the available public record.
Partial patent holder winApple: partial affirmance protects some invalidity positions
Apple benefits from the affirmed portions of the ruling, where the lower tribunal's patentability findings in its favour are now confirmed by the Federal Circuit. The reversed portions, however, represent a setback — those grounds or claims may return for further adjudication. Apple's overall exposure under US10631765B1 therefore remains partially unresolved at this appellate stage.
Partial challenger setbackWearable health IP: split rulings signal continued uncertainty
A mixed Federal Circuit outcome in a Masimo-versus-Apple patentability dispute signals that the IP landscape around noninvasive blood constituent sensing remains actively contested. Companies developing wearable health monitoring technology should treat US10631765B1 as a live enforcement risk until any remand proceedings fully resolve claim scope and validity. The decision raises the bar for design-around strategies that assumed full invalidity.
Wearable health IP riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Masimo, Corp. | Company | /Search in Eureka ↗ |
| Defendant | Apple, Inc. | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Jarom D. Kesler | Attorney | Counsel for Masimo, Corp.Search in Eureka ↗ |
| Plaintiff law firm | Knobbe Martens Olson & Bear, LLP | Law Firm | Representing Masimo, Corp.Search in Eureka ↗ |
| Defendant counsel | Walter K. Renner. | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant law firm | Fish & Richardson LLP | Law Firm | Representing Apple, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
R&D signals in noninvasive blood monitoring and wearable sensing
Forward-looking patent and innovation intelligence derived from the Masimo v. Apple Federal Circuit dispute over multi-stream noninvasive blood constituent sensing technology.
Masimo's noninvasive sensing patent family: depth and reach
US10631765B1 is one filing within Masimo's extensive physiological monitoring portfolio. Masimo has historically pursued aggressive continuation and continuation-in-part strategies around its core pulse oximetry and multi-stream sensing innovations. Mapping the full family tree around US16/725478 reveals the breadth of claim coverage that competitors must navigate in the wearable health segment.
Masimo portfolio depthMulti-stream physiological sensing: filing trends and white space
Patent filing activity in multi-stream optical sensing for wearables has accelerated alongside consumer device adoption. Identifying which sensing modalities — photoplethysmography, near-infrared spectroscopy, radar-based — are attracting new filings outside Masimo's core claim space can reveal white space for R&D differentiation and lower freedom-to-operate risk in next-generation wearable health platforms.
Sensing tech filing trendsApple's health sensing patent position in wearables
Apple has developed a substantial independent patent portfolio in wearable health sensing, covering hardware architectures, signal processing, and on-device ML inference for physiological data. Understanding Apple's own filing strategy in noninvasive monitoring — separate from its litigation posture — reveals both the scope of its design-around investments and the areas where it may seek cross-licensing leverage.
Apple Watch health IPAdjacent innovation space beyond Masimo's claim perimeter
The contested claim space around multi-stream blood constituent detection leaves adjacent technical approaches — including single-wavelength hybrid sensing, ultrasonic blood constituent estimation, and continuous glucose monitoring via impedance — potentially outside Masimo's core enforcement perimeter. Mapping these adjacencies can guide R&D investment toward defensible innovation corridors in the wearable health space.
Health sensing white spaceSimilar Federal Circuit patentability appeals in wearable health sensing
Explore related Federal Circuit invalidity and cancellation appeals involving noninvasive physiological monitoring patents and wearable medical device IP.
What this case signals for the wearable health-sensing IP landscape
Masimo v. Apple at the Federal Circuit underscores that noninvasive blood monitoring patents remain a high-stakes battleground for wearable technology.
Noninvasive blood sensing patents are not easily swept aside on appeal
A split Federal Circuit ruling — affirming some grounds, reversing others — demonstrates that Masimo's portfolio in multi-stream physiological sensing carries genuine appellate resilience. Competitors developing optical or spectroscopic wearable sensors should not rely on a single invalidity determination as a complete clearance; the reversed portions may resurrect claim scope.
Apple's partial win does not resolve its wearable health IP exposure
The affirmed portions confirm some invalidity findings in Apple's favour, but the reversal signals ongoing exposure. Product teams working on Apple Watch-adjacent health sensing features should monitor remand proceedings closely. Any design-around strategy premised on full invalidity of US10631765B1 requires reassessment in light of this mixed outcome.
Masimo v Apple — key questions answered
The Federal Circuit issued a mixed ruling: the verdict text states 'AFFIRMED-IN-PART AND REVERSED-IN-PART' on patentability grounds. The recorded basis of termination in the docket is 'Appeal Dismissed in Part.' These two characterisations are reported as-is from the public record; the specific claims or grounds falling within each part are not detailed in the available record.
The patent at issue is US10631765B1, filed under application number US16/725478. It is directed to a multi-stream data collection system for the noninvasive measurement of blood constituents — technology relevant to wearable health-sensing devices including Apple Watch.
A mixed Federal Circuit disposition on patentability means that the panel upheld some aspects of the lower tribunal's validity/invalidity findings while overturning others. The reversed portions may result in reinstatement of certain claims or remand for further proceedings. Which specific claims or grounds fall into each category is not specified in the available public record.
Masimo was represented by Jarom D. Kesler of Knobbe Martens Olson & Bear, LLP. Apple was represented by Walter K. Renner of Fish & Richardson LLP. Both are leading IP litigation firms with substantial Federal Circuit experience.
Yes, the mixed ruling means US10631765B1 cannot be treated as fully invalidated. Any prior FTO analysis premised on complete invalidity of this patent should be revisited. The reversed portions of the decision may restore claim scope that was previously considered off the table, creating residual risk for developers of noninvasive blood monitoring wearables.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.